Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.83M 3.33M 3.1M 2.84M 365M 5.45M 36.5M 14.32M 182M 14.37M 14.06M 610M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.48M 3.9M 3.63M 3.33M 428M 6.39M 42.75M 16.78M 213M 16.83M 16.46M 714M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -0.09% | +0.43% | -0.67% | +14.65% | 48.53B | |
| -1.51% | -1.37% | +398.92% | +481.69% | 39.87B | |
| -1.45% | +8.85% | +27.00% | +7.31% | 38.68B | |
| -1.26% | -4.26% | +2.54% | +51.60% | 35.13B | |
| -2.41% | +2.59% | +11.68% | +41.16% | 29.79B | |
| -0.50% | -2.28% | +33.18% | +123.19% | 16.11B | |
| +0.07% | -3.68% | - | - | 16.08B | |
| -0.65% | +1.20% | +1.77% | +15.01% | 13.61B | |
| -3.08% | -6.51% | -4.25% | -37.14% | 12.62B | |
| Average | +0.03% | +0.86% | +58.77% | +87.18% | 27.82B | |
| Weighted average by Cap. | -1.14% | +1.82% | +76.21% | +106.50% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.12M -13.14M -12.23M -11.23M -1.44B -21.54M -144M -56.6M -719M -56.79M -55.54M -2.41B | 4.21M 3M 2.61M 2.43M 2.23M 286M 4.28M 28.62M 11.23M 143M 11.27M 11.02M 478M |
| Net Debt | 704K 502K 436K 406K 373K 47.9M 715K 4.79M 1.88M 23.85M 1.88M 1.84M 79.97M | 920K 656K 570K 531K 487K 62.6M 934K 6.25M 2.45M 31.17M 2.46M 2.41M 105M |
Employees
-
